Related Articles
Targeting metastatic cancer from the inside: A new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ
First clinical experience using a ‘pathotropic’ injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer
Pathotropic nanoparticles for cancer gene therapy Rexin-G™ IV: Three-year clinical experience
Pathotropic targeting advances clinical oncology: Tumor-targeted localization of therapeutic gene delivery
Rexin‑G®, a tumor‑targeted retrovector for malignant peripheral nerve sheath tumor: A case report